Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events
Authors:
- 23 January 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 35 (3) , 110-116
Abstract
Purpose of review: Remnant cholesterol has become increasingly recognized as a direct contributor to the development of atherosclerosis and as an additional marker of cardiovascular risk. This review aims to summarize the pathophysiological mechanisms, and the current evidence base from epidemiological investigations and genetic studies that support a causal link between remnant cholesterol and atherosclerotic cardiovascular disease. Current and novel therapeutic approaches to target remnant cholesterol are discussed. Recent findings: A recent Mendelian randomization study of over 12 000 000 single-nucleotide polymorphisms associated with high levels of remnant cholesterol, demonstrated a genetic association between remnant cholesterol and adverse cardiovascular events among 958 434 participants. Summary: In this light, the emerging role of remnant cholesterol as an independent lipid risk marker warrants a reevaluation of lipid management guidelines and underscores the potential for novel therapeutic targets in cardiovascular disease prevention.Keywords
This publication has 39 references indexed in Scilit:
- Loss-of-Function Mutations inAPOC3and Risk of Ischemic Vascular DiseaseNew England Journal of Medicine, 2014
- Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatmentPharmacology & Therapeutics, 2014
- Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without InflammationCirculation, 2013
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart DiseaseJACC, 2013
- Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2012
- Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic ChallengesCurrent Atherosclerosis Reports, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Plasma lipoproteins: genetic influences and clinical implicationsNature Reviews Genetics, 2009
- A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent CardioprotectionScience, 2008
- Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart StudyAtherosclerosis, 2001